AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS

Kalaris Therapeutics, Inc.

Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.
2020 Plan amended: share reserve increased by 5% of post-merger outstanding; plan term extended to 10th anniversary of closing.
Combined company to be renamed Kalaris Therapeutics, trading on Nasdaq under ticker KLRS after closing.
Kalaris lead candidate TH103 (anti-VEGF fusion protein) in Phase 1 trial for neovascular AMD; plans for DME and RVO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.